Compare OPLN & TLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OPLN | TLX |
|---|---|---|
| Founded | 2006 | 2015 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 3.3B |
| IPO Year | N/A | N/A |
| Metric | OPLN | TLX |
|---|---|---|
| Price | $30.15 | $7.76 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $28.00 | $21.00 |
| AVG Volume (30 Days) | ★ 796.1K | 190.3K |
| Earning Date | 02-18-2026 | 01-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 357.93 | N/A |
| EPS | ★ 0.87 | 0.04 |
| Revenue | ★ $1,895,200,000.00 | $664,225,558.00 |
| Revenue This Year | $8.75 | N/A |
| Revenue Next Year | $5.09 | N/A |
| P/E Ratio | ★ $34.59 | $239.61 |
| Revenue Growth | 6.75 | ★ 55.35 |
| 52 Week Low | $17.08 | $7.31 |
| 52 Week High | $31.78 | $30.36 |
| Indicator | OPLN | TLX |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 43.28 |
| Support Level | N/A | $7.42 |
| Resistance Level | N/A | $7.71 |
| Average True Range (ATR) | 0.00 | 0.15 |
| MACD | 0.00 | 0.07 |
| Stochastic Oscillator | 0.00 | 70.31 |
Openlane Inc provides a digital marketplace for used vehicles, connecting sellers and buyers in North America and Europe for fast and transparent transactions. Its services include financing, repossessions, repairs, transportation, warranty, and inventory management. The company operates used-vehicle auctions and has two main segments: Marketplace and Finance, with majority revenue coming from the Marketplace segment, which to used vehicle remarketing, including marketplace services, remarketing, or make ready services and all are interrelated, synergistic elements along the auto remarketing chain. The Finance segment, through AFC engaged in business of providing short-term, inventory-secured financing to independent vehicle dealers.
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.